Braxia Scientific has received approval from Health Canada to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder (MDD) in Ontario.
Health Canada has granted approval to Numinus’ application to complete psychedelic-assisted therapy using psilocybin to treat an applicant with treatment-resistant depression.
A Phase II trial is being conducted to investigate the potential of psilocybin-assisted psychotherapy as a treatment for binge eating disorder (BED).
Cybin has partnered with Clinilabs to carry out its Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analogue.
Results from two-combined studies have revealed that psilocybin-assisted therapy increased brain activity in people with depression for up to three weeks following use.
Leading UK psychedelics company Compass Pathways is entering into a pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate...
Data from Wesana Health indicates that administration of imipramine given three weeks following a psilocybin loading dose provided a 39 per cent improvement in depressive behaviours...
Results from a systematic review have led to the conclusion that psilocybin is safe to administer in clinical settings, and that there is a need to...
The licence will enable research that will give a deeper understanding of psychedelic mushrooms and their interaction with the human body.